

# Guido Marcucci

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11061595/publications.pdf>

Version: 2024-02-01

187  
papers

28,201  
citations

7251

80  
h-index

6177

164  
g-index

189  
all docs

189  
docs citations

189  
times ranked

28882  
citing authors

#	ARTICLE	IF	CITATIONS
1	MicroRNA networks in FLT3-ITD acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2112482119.	3.3	5
2	Cytoplasmic DROSHA and non-canonical mechanisms of MiR-155 biogenesis in FLT3-ITD acute myeloid leukemia. Leukemia, 2021, 35, 2285-2298.	3.3	10
3	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Leukemia, 2021, 35, 2539-2551.	3.3	51
4	Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). Blood Advances, 2021, 5, 2481-2489.	2.5	25
5	Targeting BRD4 in acute myeloid leukemia with partial tandem duplication of the &lt;i>MLL</i> gene. Haematologica, 2021, 106, 2527-2532.	1.7	5
6	Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). Blood Advances, 2021, 5, 2775-2787.	2.5	15
7	Treatment-induced arteriolar revascularization and miR-126 enhancement in bone marrow niche protect leukemic stem cells in AML. Journal of Hematology and Oncology, 2021, 14, 122.	6.9	13
8	Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 580-597.	0.2	28
9	NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 16-27.	2.3	170
10	Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance. Nature Communications, 2021, 12, 6154.	5.8	27
11	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. Blood Advances, 2020, 4, 4945-4954.	2.5	34
12	Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating Functions. Blood Cancer Discovery, 2020, 1, 48-67.	2.6	30
13	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2020, 26, 1425-1432.	2.0	5
14	Venetoclax and hypomethylating agents in <i>FLT3</i>-mutated acute myeloid leukemia. American Journal of Hematology, 2020, 95, 1193-1199.	2.0	28
15	Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2020, 26, 1084-1090.	2.0	19
16	Phase I study of AR-42 and decitabine in acute myeloid leukemia. Leukemia and Lymphoma, 2020, 61, 1484-1492.	0.6	13
17	Myeloid cell-targeted miR-146a mimic inhibits NF- $\kappa$ B-driven inflammation and leukemia progression in vivo. Blood, 2020, 135, 167-180.	0.6	88
18	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood, 2020, 135, 371-380.	0.6	127

#	ARTICLE	IF	CITATIONS
19	Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. <i>Blood Advances</i> , 2020, 4, 696-705.	2.5	44
20	The emerging story of acute lymphoblastic leukemia among the Latin American population – biological and clinical implications. <i>Blood Reviews</i> , 2019, 33, 98-105.	2.8	38
21	Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e400-e405.	0.2	12
22	ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model. <i>Blood</i> , 2019, 134, 432-444.	0.6	32
23	Targeted Delivery of miRNA Antagonists to Myeloid Cells In Vitro and In Vivo. <i>Methods in Molecular Biology</i> , 2019, 1974, 141-150.	0.4	3
24	Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.5	11
25	A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. <i>Blood</i> , 2019, 133, 1548-1559.	0.6	292
26	A novel regimen for relapsed/refractory adult acute myeloid leukemia using a <i>KMT2A</i> partial tandem duplication targeted therapy: results of phase 1 study NCI 8485. <i>Haematologica</i> , 2018, 103, 982-987.	1.7	16
27	R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling. <i>Cell</i> , 2018, 172, 90-105.e23.	13.5	794
28	Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). <i>Blood Advances</i> , 2018, 2, 3608-3617.	2.5	39
29	Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (Iâ€•CBF) Tj ETQq1 1 0.784314 rgBT	1.8	17
30	High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. <i>Journal of Clinical Oncology</i> , 2017, 35, 394-401.	0.8	326
31	Antileukemic activity and cellular effects of the antimalarial agent artesunate in acute myeloid leukemia. <i>Leukemia Research</i> , 2017, 59, 124-135.	0.4	22
32	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation. <i>New England Journal of Medicine</i> , 2017, 377, 454-464.	13.9	1,628
33	Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E4641-E4647.	3.3	36
34	Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. <i>Nature Communications</i> , 2016, 7, 13331.	5.8	218
35	Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2016, 48, 1481-1489.	9.4	231
36	Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat. <i>Blood</i> , 2016, 128, 1166-1166.	0.6	5

#	ARTICLE	IF	CITATIONS
37	Targeting the RAS/MAPK pathway with <i>miR-181a</i> in acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 59273-59286.	0.8	50
38	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. <i>Blood</i> , 2015, 125, 680-686.	0.6	110
39	Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia. <i>Blood</i> , 2015, 125, 2689-2692.	0.6	47
40	Genetics and Classification of Acute Myeloid Leukemia. , 2015, , 1-25.		0
41	Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia. <i>Current Opinion in Hematology</i> , 2015, 22, 85-91.	1.2	32
42	Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv274.	3.0	80
43	Promoter-Specific Hypomethylation Is Associated with Overexpression of PLS3 , GATA6 , and TWIST1 in the Sezary Syndrome. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2084-2092.	0.3	32
44	Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 1304-1308.	0.6	23
45	Expression and prognostic impact of lncRNAs in acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 18679-18684.	3.3	214
46	Intronic <i>miR-3151</i> Within <i>BAALC</i> Drives Leukemogenesis by Deregulating the TP53 Pathway. <i>Science Signaling</i> , 2014, 7, ra36.	1.6	18
47	Epigenetics Meets Genetics in Acute Myeloid Leukemia: Clinical Impact of a Novel Seven-Gene Score. <i>Journal of Clinical Oncology</i> , 2014, 32, 548-556.	0.8	134
48	Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8. <i>Leukemia</i> , 2014, 28, 1754-1758.	3.3	24
49	PrEMeR-CG: inferring nucleotide level DNA methylation values from MethylCap-seq data. <i>Bioinformatics</i> , 2014, 30, 3567-3574.	1.8	11
50	Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 1005-1015.	13.9	1,161
51	GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. <i>Leukemia</i> , 2014, 28, 1252-1258.	3.3	45
52	Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2014, 4, 362-375.	7.7	561
53	Identification of Medium-Sized Copy Number Alterations in Whole-Genome Sequencing. <i>Cancer Informatics</i> , 2014, 13s3, CIN.S14023.	0.9	0
54	Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML. <i>Blood</i> , 2014, 123, 2412-2415.	0.6	43

#	ARTICLE	IF	CITATIONS
55	Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells. <i>Blood</i> , 2014, 124, 1127-1135.	0.6	55
56	Management of Patients With Cytogenetically Normal Acute Myeloid Leukemia Who Have Neither Favorable nor Unfavorable Markers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 527-534.	2.3	4
57	SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. <i>Journal of Clinical Investigation</i> , 2014, 124, 1512-1524.	3.9	52
58	Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2013, 6, 21.	6.9	49
59	In Vivo Quantification of Active Decitabine-Triphosphate Metabolite: A Novel Pharmacanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia. <i>AAPS Journal</i> , 2013, 15, 242-249.	2.2	16
60	Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults. <i>British Journal of Haematology</i> , 2013, 161, 406-410.	1.2	42
61	Identification of a 24-Gene Prognostic Signature That Improves the European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: An International Collaborative Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 1172-1181.	0.8	164
62	Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. <i>Blood</i> , 2013, 122, 3034-3044.	0.6	132
63	Detection of Extracellular RNAs in Cancer and Viral Infection via Tethered Cationic Lipoplex Nanoparticles Containing Molecular Beacons. <i>Analytical Chemistry</i> , 2013, 85, 11265-11274.	3.2	56
64	Eradicating acute myeloid leukemia in a MllPTD/wt:Flt3ITD/wt murine model: a path to novel therapeutic approaches for human disease. <i>Blood</i> , 2013, 122, 3778-3783.	0.6	28
65	Lenalidomide-mediated enhanced translation of C/EBP $\beta$ -p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. <i>Blood</i> , 2013, 121, 159-169.	0.6	56
66	Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway. <i>Blood</i> , 2013, 121, 499-509.	0.6	143
67	Targeted Delivery of microRNA-29b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2013, 19, 2355-2367.	3.2	170
68	Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients. <i>Journal of Clinical Oncology</i> , 2013, 31, 2086-2093.	0.8	165
69	Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 136-147.	0.6	63
70	inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFb-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations. <i>Blood</i> , 2013, 121, 385-391.	0.6	39
71	Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod), Tj ETQq1 1 0.784314 rgBT /Overlock 104	0.6	104
72	PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. <i>Journal of Clinical Investigation</i> , 2013, 123, 4144-4157.	3.9	192

#	ARTICLE	IF	CITATIONS
73	Potential of microRNAs for cancer diagnostics, prognostication and therapy. <i>Current Opinion in Oncology</i> , 2012, 24, 655-659.	1.1	63
74	Heritable polymorphism predisposes to high <i>BAALC</i> expression in acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 6668-6673.	3.3	23
75	Acute Myeloid Leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 984-1021.	2.3	236
76	Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. <i>Blood</i> , 2012, 120, 1765-1773.	0.6	192
77	Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. <i>Blood</i> , 2012, 120, 2466-2474.	0.6	74
78	Aberrant Overexpression of IL-15 Initiates Large Granular Lymphocyte Leukemia through Chromosomal Instability and DNA Hypermethylation. <i>Cancer Cell</i> , 2012, 22, 645-655.	7.7	150
79	Molecular prognostic factors in cytogenetically normal acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2012, 5, 547-558.	1.0	32
80	Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. <i>Blood</i> , 2012, 119, 2314-2324.	0.6	145
81	RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. <i>Blood</i> , 2012, 119, 5229-5238.	0.6	115
82	Synthetic MicroRNA Cassette Dosing: Pharmacokinetics, Tissue Distribution and Bioactivity. <i>Molecular Pharmaceutics</i> , 2012, 9, 1638-1644.	2.3	24
83	Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 4515-4523.	0.8	363
84	A 75-Year-Old Woman With Thoracic Spinal Cord Compression and Chloroma (granulocytic sarcoma). <i>Seminars in Oncology</i> , 2012, 39, e37-e46.	0.8	6
85	Enrichment-based DNA methylation analysis using next-generation sequencing: sample exclusion, estimating changes in global methylation, and the contribution of replicate lanes. <i>BMC Genomics</i> , 2012, 13, S6.	1.2	10
86	Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. <i>Blood</i> , 2012, 119, 6025-6031.	0.6	127
87	miR-3151 interplays with its host gene <i>BAALC</i> and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. <i>Blood</i> , 2012, 120, 249-258.	0.6	64
88	<i>RUNX1</i> Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures. <i>Journal of Clinical Oncology</i> , 2012, 30, 3109-3118.	0.8	242
89	Age-Related Prognostic Impact of Different Types of <i>DNMT3A</i> Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 742-750.	0.8	244
90	<i>TET2</i> Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 1373-1381.	0.8	291

#	ARTICLE	IF	CITATIONS
91	Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Haematologica</i> , 2011, 96, 1488-1495.	1.7	20
92	Epigenetic priming: the target?. <i>Blood</i> , 2011, 118, 1430-1431.	0.6	1
93	Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. <i>Blood</i> , 2011, 118, 4188-4198.	0.6	52
94	ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. <i>Blood</i> , 2011, 118, 6920-6929.	0.6	246
95	Acute Myeloid Leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 280-317.	2.3	56
96	NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, S-1-S-32.	2.3	227
97	Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications. <i>Journal of Clinical Oncology</i> , 2011, 29, 475-486.	0.8	510
98	The prognostic and functional role of microRNAs in acute myeloid leukemia. <i>Blood</i> , 2011, 117, 1121-1129.	0.6	247
99	Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling. <i>Cancer</i> , 2011, 117, 4696-4706.	2.0	55
100	Impact of molecular prognostic factors in cytogenetically normal acute myeloid leukemia at diagnosis and relapse. <i>Haematologica</i> , 2011, 96, 640-643.	1.7	13
101	Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. <i>Blood</i> , 2011, 117, 5941-5952.	0.6	101
102	FTY720 Restores PP2A Tumor Suppressor Activity in Polycythemia Vera CD34+ Progenitors Through Inhibition of Jak2 V617F- and PI-3K $\beta$ -Dependent SET Serine Phosphorylation and Enhancement of NOS-Dependent PP2A Tyrosine Nitration. <i>Blood</i> , 2011, 118, 2494-2494.	0.6	3
103	Prognostic Significance of Karyotype in Octogenarian Patients (Pts) with Acute Myeloid Leukemia (AML) – An International Study. <i>Blood</i> , 2011, 118, 2521-2521.	0.6	1
104	Prognostic Utility of the European LeukemiaNet (ELN) Genetic-Risk Classification in Adults with De Novo Acute Myeloid Leukemia (AML): A Study of 1,550 Patients (Pts). <i>Blood</i> , 2011, 118, 414-414.	0.6	2
105	Impact of DNMT3A mutations on Clinical Response to the Hypomethylating Agent Decitabine in Older Patients (pts) with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2011, 118, 944-944.	0.6	1
106	Translational Research From the Tropical Forest: Silvestrol, a Natural Product From the Plant <i>Aglaia Foveolata</i> inhibits the Expression of Tyrosine Kinases and Shows a Significant In Vivo Activity in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2011, 118, 2616-2616.	0.6	0
107	Poor Outcome of RUNX1-Mutated (RUNX1-mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures. <i>Blood</i> , 2011, 118, 3454-3454.	0.6	0
108	MLL-PTD Causes Hypomorph Condition of CBF Complex (RUNX1/CBF $\beta$ ) and Predisposes the Abnormal Hematopoietic Stem and Progenitor Cells (HSPCs) to Clonal Expansion. <i>Blood</i> , 2011, 118, 2801-2801.	0.6	4

#	ARTICLE	IF	CITATIONS
109	Cytogenetic, Molecular and Clinical Features Associated with Rare CBFβ-MYH11 Fusion Transcripts in Patients (Pts) with Acute Myeloid Leukemia (AML) and inv(16)/t(16;16). <i>Blood</i> , 2011, 118, 2514-2514.	0.6	0
110	Combined Pharmacologic Inhibition of Bcl-XL/Bcl-2 and mTORC1/2 Survival Signals Trigger Apoptosis in BCR-ABL1+in Vitro Models of Blast Crisis Chronic Myelogenous Leukemia (CML-BC), and Primary CD34+/CD38 <sup>+</sup> Stem and CD34+ progenitor Cells From CML-BC Patients. <i>Blood</i> , 2011, 118, 2738-2738.	0.6	0
111	Nuclear Export (Karyopherin) Inhibitors: A Novel Therapeutic Strategy for Treating Blast Crisis Chronic Myelogenous Leukemia (CML) and Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Through Interference with hnRNP Nucleocytoplasmic Shuttling and Rescue of Protein Phosphatase 2A (PP2A) Tumor Suppressor Activity. <i>Blood</i> , 2011, 118, 3758-3758.	0.6	0
112	Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials. <i>Blood</i> , 2011, 118, 1791-1791.	0.6	0
113	MiR-3151, a Novel MicroRNA Embedded in BAALC, Is Only Weakly Co-Expressed with Its Host Gene and Independently Impacts on the Clinical Outcome of Older Patients (Pts) with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). <i>Blood</i> , 2011, 118, 1462-1462.	0.6	0
114	A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia. <i>Blood</i> , 2010, 115, 2462-2472.	0.6	46
115	FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Blood</i> , 2010, 116, 3622-3626.	0.6	201
116	A Novel Ultrasensitive Hybridization-Based ELISA Method for 2-Methoxyphosphorothiolate MicroRNAs and Its In vitro and In vivo Application. <i>AAPS Journal</i> , 2010, 12, 556-568.	2.2	19
117	Sp1/NF $\kappa$ B/HDAC/miR-29b Regulatory Network in KIT-Driven Myeloid Leukemia. <i>Cancer Cell</i> , 2010, 17, 333-347.	7.7	235
118	Targeting microRNAs in cancer: rationale, strategies and challenges. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 775-789.	21.5	1,308
119	Prognostic Significance of Expression of a Single MicroRNA, <i>miR-181a</i> , in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 5257-5264.	0.8	176
120	Clinical response and <i>miR-29b</i> predictive significance in older AML patients treated with a 10-day schedule of decitabine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 7473-7478.	3.3	443
121	Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias. <i>Journal of Clinical Oncology</i> , 2010, 28, 4919-4925.	0.8	82
122	<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 2348-2355.	0.8	699
123	<i>miR-328</i> Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic Blasts. <i>Cell</i> , 2010, 140, 652-665.	13.5	514
124	BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Blood</i> , 2010, 116, 5660-5669.	0.6	110
125	Favorable Prognostic Impact of <i>NPM1</i> Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 596-604.	0.8	305
126	Modulation of DNA Methylation by a Sesquiterpene Lactone Parthenolide. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 329, 505-514.	1.3	133



#	ARTICLE	IF	CITATIONS
127	MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. <i>Blood</i> , 2009, 113, 6411-6418.	0.6	729
128	Molecular signatures in acute myeloid leukemia. <i>Current Opinion in Hematology</i> , 2009, 16, 64-69.	1.2	41
129	Prognostic Importance of <i>MN1</i> Transcript Levels, and Biologic Insights From <i>MN1</i> -Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 3198-3204.	0.8	149
130	MicroRNA expression in acute myeloid leukemia. <i>Current Hematologic Malignancy Reports</i> , 2009, 4, 83-88.	1.2	44
131	MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 239-248.	0.7	26
132	MicroRNA 29b functions in acute myeloid leukemia. <i>Blood</i> , 2009, 114, 5331-5341.	0.6	412
133	Evidence of MicroRNA-29b and Sp1/NF $\kappa$ B-HDAC Regulatory Network for KIT Expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications.. <i>Blood</i> , 2009, 114, 938-938.	0.6	1
134	Epigenetics in Acute Myeloid Leukemia. <i>Seminars in Oncology</i> , 2008, 35, 378-387.	0.8	82
135	New approaches in acute myeloid leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2008, 21, 29-41.	0.7	8
136	Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. <i>Current Opinion in Oncology</i> , 2008, 20, 711-718.	1.1	79
137	Epigenetic Modification of CCAAT/Enhancer Binding Protein $\beta$ Expression in Acute Myeloid Leukemia. <i>Cancer Research</i> , 2008, 68, 3142-3151.	0.4	139
138	MicroRNA Expression in Cytogenetically Normal Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2008, 358, 1919-1928.	13.9	427
139	Wilms' Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults With Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 4595-4602.	0.8	230
140	Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, <i>CEBPA</i> Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 5078-5087.	0.8	294
141	MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. <i>Blood</i> , 2008, 111, 3183-3189.	0.6	575
142	Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. <i>Blood</i> , 2008, 111, 816-828.	0.6	44
143	FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. <i>Blood</i> , 2008, 111, 1552-1559.	0.6	243
144	Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF $\kappa$ B-dependent DNA methyltransferase activity in acute myeloid leukemia. <i>Blood</i> , 2008, 111, 2364-2373.	0.6	132

#	ARTICLE	IF	CITATIONS
145	High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. <i>Blood</i> , 2008, 111, 5371-5379.	0.6	174
146	An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. <i>Blood</i> , 2008, 112, 4193-4201.	0.6	357
147	Importance of FLT3 Mutations and Other Genetic Abnormalities in Normal Karyotype AML. <i>Blood</i> , 2008, 112, sci-11-sci-11.	0.6	0
148	High Expression Levels of the ETS-Related Gene, ERG, Predict Adverse Outcome and Improve Molecular Risk-Based Classification of Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 3337-3343.	0.8	184
149	Phase I Study of Decitabine Alone or in Combination With Valproic Acid in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2007, 25, 3884-3891.	0.8	324
150	Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?. <i>Blood</i> , 2007, 109, 431-448.	0.6	507
151	Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. <i>Blood</i> , 2007, 109, 5164-5167.	0.6	92
152	MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 15805-15810.	3.3	1,538
153	Targeting AML1/ETO-Histone Deacetylase Repressor Complex: A Novel Mechanism for Valproic Acid-Mediated Gene Expression and Cellular Differentiation in AML1/ETO-Positive Acute Myeloid Leukemia Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 321, 953-960.	1.3	77
154	Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method. <i>Nucleic Acids Research</i> , 2007, 35, e31-e31.	6.5	71
155	Histone H4 N-Terminal Acetylation in Kasumi-1 Cells Treated with Depsipeptide Determined by Acetic Acid-Urea Polyacrylamide Gel Electrophoresis, Amino Acid Coded Mass Tagging, and Mass Spectrometry. <i>Journal of Proteome Research</i> , 2007, 6, 81-88.	1.8	20
156	Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review. <i>British Journal of Haematology</i> , 2007, 137, 387-400.	1.2	97
157	FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. <i>Journal of Clinical Investigation</i> , 2007, 117, 2408-2421.	3.9	308
158	Dual Epigenetic Control of CCAAT/Enhancer Binding Protein $\pm$ (C/EBP $\pm$ ) Expression in Acute Myeloid Leukemia. <i>Blood</i> , 2007, 110, 2116-2116.	0.6	1
159	MiRNA-29b Targets MCL-1 and Is Down-Regulated in Chemotherapy-Resistant Acute Myeloid Leukemia (AML). <i>Blood</i> , 2007, 110, 717-717.	0.6	4
160	A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. <i>Blood</i> , 2006, 107, 2507-2516.	0.6	174
161	Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. <i>Blood</i> , 2006, 108, 1677-1683.	0.6	123
162	MicroRNA fingerprints during human megakaryocytopoiesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 5078-5083.	3.3	403

#	ARTICLE	IF	CITATIONS
163	Adverse Prognostic Significance of KIT Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 3904-3911.	0.8	618
164	Updated Results of a Phase I Study of Flavopiridol in Acute Leukemias Using a Novel, Pharmacokinetically Derived Schedule: Clinical Activity Including Hyperacute Tumor Lysis Syndrome (TLS), Pharmacokinetics (PK), and Pharmacodynamics (PD).. <i>Blood</i> , 2006, 108, 4578-4578.	0.6	0
165	Bortezomib-Induced Down-Regulation of KIT Is Mediated by Inhibition of Sp1 and NF- $\kappa$ B in AML1/ETO-Positive Cells.. <i>Blood</i> , 2006, 108, 4211-4211.	0.6	0
166	Imatinib Mesylate-Induced Complete Cytogenetic Response in Acute Myeloid Leukemia with t(5;12)(q33;p13).. <i>Blood</i> , 2006, 108, 4414-4414.	0.6	0
167	The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. <i>Blood</i> , 2005, 106, 345-352.	0.6	128
168	The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. <i>Cancer Cell</i> , 2005, 8, 355-368.	7.7	433
169	Overexpression of the ETS-Related Gene, ERG, Predicts a Worse Outcome in Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 9234-9242.	0.8	226
170	Interplay of RUNX1/MTG8 and DNA Methyltransferase 1 in Acute Myeloid Leukemia. <i>Cancer Research</i> , 2005, 65, 1277-1284.	0.4	133
171	Chemoresistance to Depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-Ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentakis(1,3,3-trimethylbutyl)phosphorodithioate] Is Mediated by Reversible MDR1 Induction in Human Cancer Cell Lines. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 314, 467-475.	1.3	63
172	Bioavailability of Azacitidine Subcutaneous Versus Intravenous in Patients With the Myelodysplastic Syndromes. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 597-602.	1.0	129
173	Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 5705-5717.	0.8	324
174	Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical Activity. <i>Journal of Clinical Oncology</i> , 2005, 23, 3404-3411.	0.8	143
175	A Randomized Comparison of Induction Therapy for Untreated Acute Myeloid Leukemia (AML) in Patients $\geq$ 60 Years Using P-Glycoprotein (Pgp) Modulation with Valspodar (PSC833): Preliminary Results of Cancer and Leukemia Group B Study 19808.. <i>Blood</i> , 2005, 106, 407-407.	0.6	19
176	ReSETting PP2A Tumor Suppressor Activity Overcomes BCR/ABL Leukemogenic Potential in Blast Crisis CML.. <i>Blood</i> , 2005, 106, 1992-1992.	0.6	8
177	BCR/ABL Post-Translationally Enhances hnRNP E2 Expression and Translation-Inhibitory Function through the Activation of ERK1/2 Mitogen-Activated Protein Kinases.. <i>Blood</i> , 2005, 106, 4376-4376.	0.6	0
178	Abnormal Cytogenetics at Date of Morphologic Complete Remission Predicts Short Overall and Disease-Free Survival, and Higher Relapse Rate in Adult Acute Myeloid Leukemia: Results From Cancer and Leukemia Group B Study 8461. <i>Journal of Clinical Oncology</i> , 2004, 22, 2410-2418.	0.8	101
179	A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. <i>Blood</i> , 2004, 105, 959-967.	0.6	371
180	Elucidation of the Molecular Mechanisms by Which Inflammatory and Anti-Inflammatory Monokines Regulate Interferon (IFN)- $\beta$ Production.. <i>Blood</i> , 2004, 104, 111-111.	0.6	2

#	ARTICLE	IF	CITATIONS
181	Incidence of Extramedullary Relapse of Acute Myeloid Leukemia Following Transplantation with Busulfan-Based Conditioning Regimens.. Blood, 2004, 104, 5123-5123.	0.6	1
182	Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically?. European Journal of Haematology, 2003, 71, 143-154.	1.1	23
183	Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood, 2003, 102, 652-658.	0.6	163
184	BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood, 2003, 102, 1613-1618.	0.6	222
185	Depsipeptide (FR901228) Inhibits Proliferation and Induces Apoptosis in Primary and Metastatic Human Uveal Melanoma Cell Lines. , 2003, 44, 2390.		54
186	Comparison of Cytogenetic and Molecular Genetic Detection of t(8;21) and inv(16) in a Prospective Series of Adults With De Novo Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2001, 19, 2482-2492.	0.8	94
187	Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene. Oncogene, 1999, 18, 3159-3165.	2.6	54